FDA & Government News

May 21, 2026

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

Conexiant

May 20, 2026

FDA Approves Expanded Liquid Biopsy Panel

Updated liquid biopsy combines genomic and epigenomic profiling for companion diagnostic use across multiple tumor types.

Conexiant

May 12, 2026

Makary Resigns as FDA Commissioner Following Policy Disputes

Transition follows disputes over vaccine policy, food additive regulation, and flavored vaping product authorization

Conexiant

May 11, 2026

New Label Expansion in Generalized Myasthenia Gravis

Phase 3 ADAPT SERON data supported efgartigimod use across antibody subtypes often underrepresented in trials.

Conexiant

May 04, 2026

FDA Expands ASCENIV Pediatric Use

Label change follows completion of required pediatric evaluation and updates prior age restrictions for treatment eligibility.

Conexiant

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

April 29, 2026

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Conexiant

April 28, 2026

FDA Clears Breztri for Asthma Use

Single-inhaler triple therapy improved lung function vs dual therapy in phase 3 trials and showed rapid onset without new safety signals.

Conexiant

April 02, 2026

CDC Lists Dozens of Infectious Disease Tests as Unavailable

More than two dozen assays paused or discontinued, with alternative testing options noted

Conexiant

April 01, 2026

FDA Broadens CFTR Therapy Eligibility

The FDA expanded use of CFTR modulators to include more CF gene variants, increasing treatment eligibility across a wider US patient population.

Conexiant

March 30, 2026

FDA Updates SMA Treatment Dosing

A higher-dose nusinersen regimen for spinal muscular atrophy demonstrated statistically significant motor function improvement in treatment-naïve infants in the DEVOTE trial with a safety profile consistent with prior dosing.

Conexiant

LC9 Scores Tied to Better Lung Health in NHANES Analysis

FDA & Government News

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

FDA Approves Expanded Liquid Biopsy Panel

Makary Resigns as FDA Commissioner Following Policy Disputes

New Label Expansion in Generalized Myasthenia Gravis

FDA Expands ASCENIV Pediatric Use

Daily News

FDA Monthly Preview: Key May Decisions to Watch

FDA Clears Breztri for Asthma Use

CDC Lists Dozens of Infectious Disease Tests as Unavailable

FDA Broadens CFTR Therapy Eligibility

FDA Updates SMA Treatment Dosing

Recommendations

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Trending Now

LC9 Scores Tied to Better Lung Health in NHANES Analysis

Trending Now

Find topic & conditions by first letter

Compendium

Inside Dental Hygiene

Inside Dental Technology

Inside Dentistry

The ASCO Post

JADPRO

JNCCN

JNCCN 360

Corneal Physician

Glaucoma Physician

New Retinal Physician

Ophthalmology Management

Ophthalmic Professional

Presbyopia Physician

Retinal Physician

The Ophthalmologist

Contact Lens Spectrum

Eyecare Business

Optometric Management

Presbyopia Physician

The New Optometrist

The Pathologist

FDA & Government News

Daily News

Recommendations